Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy.

Author(s): Serebruany V, Sani Y, Eisert C, Schevchuck A, Fong A, Hanley D

Affiliation(s): Johns Hopkins University, Baltimore, Maryland, 21204, USA. heartdrug@aol.com

Publication date & source: 2011-01, Thromb Haemost., 105(1):81-7. Epub 2010 Oct 26.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Plasma endothelial nitric oxide synthase (eNOS), and oxidised low-density lipoproteins (oxLDL) are established biomarkers of atherosclerosis. We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients. Baseline pretreatment eNOS levels were significantly diminished (110 +/- 66pg /ml vs. 374 +/- 88 pg/ml, p=0.0001), while oxLDL was twice higher (58 +/- 9 mg/l vs. 23 +/- 7 mg/l, p=0.004) in post-stroke survivors when compared to controls. Both Aggrenox and aspirin similarly increased plasma eNOS activity. However, oxLDL levels were static after aspirin, but inhibited late after Aggrenox. In the small randomised study, both aspirin and Aggrenox produced fast and sustained recovery of plasma eNOS levels, while only therapy with Aggrenox was associated with oxLDL inhibition late in the trial.